CONTACT
A REP
IR=intolerance or inadequate response;
TNFi=tumor necrosis factor inhibitor
US-MULT-240253
IR=intolerance or inadequate response;
TNFi=tumor necrosis factor inhibitor
RINVOQ is indicated for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers.
Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for ulcerative colitis, or with other potent immunosuppressants such as azathioprine and cyclosporine.